NanoMedSyn offers a bioengineering platform using AMFA glycovectors targeting the mannose 6-phosphate receptor to create first-in-class drugs. These AMFA vectors are grafted onto therapeutic antibodies, enzymes or nanoparticles to allow their cellular internalisation and routing to lysosomes. NanoMedSyn will be the partner for the AMFA-coupling and characterisation of your new drug.
Our objectives
Based on AMFA
NanoMedSyn’s development plan is based on a strong intellectual property of patented synthetic derivatives called AMFA.
The main application
is the engineering of recombinant proteins like antibodies or enzymes for better therapies.
Development
NanoMedSyn develops engineered therapeutics in-house and in partnership.